Bioventus BVS U.S. — Total Net Sales
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Bioventus in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The official record: Bioventus’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Bioventus's u.s. — total net sales.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Bioventus's U.S. — total net sales?
- Bioventus (BVS) reported U.S. — total net sales of $116.45M in Q1 2026.
- How has Bioventus's U.S. — total net sales changed year-over-year?
- Bioventus's U.S. — total net sales increased by 5.4% year-over-year, from $110.52M to $116.45M.
- What is the long-term trend for Bioventus's U.S. — total net sales?
- Over 4 years (2021 to 2025), Bioventus's U.S. — total net sales has grown at a 6.7% compound annual growth rate (CAGR), from $387.55M to $502.1M.
- What does U.S. — total net sales mean?
- Represents the total revenue generated from the sale of medical products and services within the U.S. geographic segment, net of returns, allowances, and discounts. This is the primary measure of market demand and commercial success for the company's domestic operations. It serves as a fundamental indicator of top-line growth and market penetration.